1. Zn-based physiometacomposite nanoparticles: distribution, tolerance, imaging, and antiviral and anticancer activity
- Author
-
Sarah Young, Sagar Rayamajhi, Rowena A. Woode, Santosh Aryal, Sarah Schneider, Garry Glaspell, Steve Ensley, Tracy Miesner, Kartik Ghosh, Robert K. Delong, Pratiksha Khanal, Heman Shakeri, Zhoumeng Lin, Megan C. Niederwerder, Lane L. Clarke, Mary Lynn Higginbotham, Majid Jaberi-Douraki, Tej B. Shrestha, Elza Neelima Mathew, Ryan Swanson, Reza Mazloom, and Ramesh Marasini
- Subjects
Luminescence ,Cell Survival ,Swine ,Cell ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,Spleen ,02 engineering and technology ,Development ,Antiviral Agents ,law.invention ,Flow cytometry ,Mice ,03 medical and health sciences ,Confocal microscopy ,law ,Cell Line, Tumor ,medicine ,Organoid ,Animals ,Distribution (pharmacology) ,General Materials Science ,Viability assay ,030304 developmental biology ,0303 health sciences ,medicine.diagnostic_test ,Chemistry ,021001 nanoscience & nanotechnology ,Molecular biology ,Zinc ,medicine.anatomical_structure ,Nanoparticles ,0210 nano-technology ,Ex vivo - Abstract
The aim of this study was to investigate the distribution, tolerance, and anticancer and antiviral activity of Zn-based physiometacomposites (PMCs). Manganese, iron, nickel and cobalt-doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3D culture and mice, and biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver >spleen >kidney >lung >brain, without tissue or blood pathology. Photophysical characterization as ex vivo tissue probes and LL37 peptide, antisense oligomer or aptamer delivery targeting RAS/Ras binding domain (RBD) was investigated. Treatment at 25 μg/ml for 48 h showed ≥98–99% cell viability, 3D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease.
- Published
- 2021
- Full Text
- View/download PDF